Navigation Links
Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
Date:11/3/2009

WALTHAM, Mass, Nov. 3 /PRNewswire/ -- On-Q-ity, a next-generation oncology diagnostics company focused on improving cancer therapy effectiveness, announced today that it has closed a $21 million series A financing. The funding was led by MDV-Mohr Davidow Ventures and included Bessemer Venture Partners, Physic Ventures and Northgate Capital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

On-Q-ity is developing diagnostics to determine optimal treatment choice for cancer patients at each stage of the treatment cycle - from the first therapy choice to monitoring for recurrence. The company's novel circulating tumor cell (CTC) technology and predictive biomarker platform allows for the analysis of tumor tissue samples as well as the capture of rare tumors cells that are circulating in a cancer patient's blood. Those cells are then monitored for molecular changes that are characteristic of therapy response. This combination enables minimally invasive real-time data on a patient's status - allowing treatment adjustments before changes are visible with any other technology.

Mara Aspinall is President and Chief Executive Officer of On-Q-ity and a leader in the fields of diagnostics, oncology and personalized medicine. Formerly president of Genzyme Genetics, she expanded the business' scope and market reach to become one of the nation's largest diagnostic laboratories. She described On-Q-ity's technology as a paradigm shift in cancer care, explaining, "We will enable physicians to confidently choose effective therapy and then actively monitor their patients' treatment response or resistance. By using CTCs and predictive DNA repair biomarkers, we can help quickly determine if a therapy is working and reduce the cost as well as the loss of critical time associated with ineffective treatments. Through ongoing personalized diagnosis, we hope to improve patient care and, ultimately, increase survival rates."

Sue Siegel, MDV Partner and On-Q-ity board member, added, "Mara has been at the forefront of personalized medicine and has a proven ability to bring new diagnostics to market. We are excited that the combination of a strong seasoned team and On-Q-ity's arsenal of proprietary technologies can play a key role in our nation's war on cancer and improve patient care while reducing healthcare costs."

In addition to Siegel, Steve Kraus from Bessemer Venture Partners and Dion Madsen from Physic Ventures will join the On-Q-ity board of directors.

About On-Q-ity

On-Q-ity is a next-generation diagnostics company focused on transforming cancer treatment and improving treatment outcomes for cancer patients. The Company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the progress of treatment. On-Q-ity was formed earlier this year through the merger of Cellective DX, a developer of microfluidics devices to detect and capture rare circulating tumor cells from the blood of cancer patients, with The DNA Repair Company, a molecular diagnostics company developing biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors.

The company's CTC and biomarker technologies originated from ground-breaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively. The privately-held company, headquartered in Waltham, MA, is funded by Bessemer Venture Partners, MDV-Mohr Davidow Ventures, Physic Ventures and Northgate Capital. For more information, visit: www.On-Q-ity.com.

SOURCE MDV-Mohr Davidow Ventures


'/>"/>
SOURCE MDV-Mohr Davidow Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ScandiDos Sells 100th Delta4(R) PT Unit as Adoption of Rotational Therapy Cancer Treatment Increases
2. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
3. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
4. superDimension Launches Second Generation iLogic(TM)Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer
5. Cancer Treatment Guidelines for Diverse Asian Economies Use Model Developed at Fred Hutchinson Cancer Research Center
6. High-Resolution Breast PET Improves Breast Cancer Detection
7. Breast Health is a Year-Round Priority: New Technology Identifies Risk of Breast Cancer in Younger Women
8. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
9. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
10. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
11. November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... Leadership of Life Science Logistics (LSL), a ... earned its ISO 13485 certification, indicating the company’s quality control system for medical ... associated with ISO quality standard 13485. , BSI Group America, Inc., a ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that doesn't sacrifice taste? ... has ignited an undeniable buzz in the protein product community by offering an alternative ... These doughnuts are packed with 11 grams of protein and made from a healthy ...
(Date:5/26/2016)... Boston, MA (PRWEB) , ... May 26, 2016 ... ... working to enhance surgical safety efforts for several years, and the efforts have ... significantly decreased. These efforts include new standards of care to enhance perioperative patient ...
Breaking Medicine News(10 mins):